RETROVIR Drug Patent Profile

When do Retrovir patents expire, and when can generic versions of Retrovir launch?

Retrovir is a drug marketed by Viiv Hlthcare and is included in four NDAs.

The generic ingredient in RETROVIR is zidovudine. There are twenty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the zidovudine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Retrovir

A generic version of RETROVIR was approved as zidovudine by AUROBINDO on September 19^th, 2005.

Summary for RETROVIR

US Patents:	0
Applicants:	1
NDAs:	4

US Patents and Regulatory Information for RETROVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	RETROVIR	zidovudine	CAPSULE;ORAL	019655-001	Mar 19, 1987	AB	RX	Yes	Yes
Viiv Hlthcare	RETROVIR	zidovudine	TABLET;ORAL	020518-001	Dec 19, 1995		DISCN	No	No
Viiv Hlthcare	RETROVIR	zidovudine	INJECTABLE;INJECTION	019951-001	Feb 2, 1990		RX	Yes	Yes
Viiv Hlthcare	RETROVIR	zidovudine	SOLUTION;ORAL	019910-001	Sep 28, 1989	AA	RX	Yes	Yes
Viiv Hlthcare	RETROVIR	zidovudine	TABLET;ORAL	020518-002	Oct 4, 1996		DISCN	Yes	No

International Patents for RETROVIR

See the table below for patents covering RETROVIR around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	215486	3'-AZIDO-3'-DEOXYTHYMIDINE ANTIRETROVIRAL COMPOSITIONS (ZIDOVUDINE, AZT)
Portugal	83375	PROCESSO PARA A PREPARACAO DE 3'-AZIDO-NUCLEOSIDOS E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM
Japan	S61257925	ANTIVIRAL NUCLEOSIDE
Australia	572019
United Kingdom	8603450

Supplementary Protection Certificates for RETROVIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0513917	98C0020	Belgium		PRODUCT NAME: LAMIVUDINE/ZIDOVUDINE; REGISTRATION NO/DATE: EU/1/98/058/001 19980318
0513917	C980018	Netherlands		PRODUCT NAME: LAMIVUDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ZIDOVUDINE; REGISTRATION NO/DATE: EU/1/98/058/001-002 19980318
0513917	SPC/GB98/019	United Kingdom		PRODUCT NAME: A COMBINATION COMPRISING LAMIVUDINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND ZIDOVUDINE; REGISTERED: UK EU/1/98/058/001 19980318; UK EU/1/98/058/002 19980318

Investment Scenario, Market Dynamics, and Financial Trajectory for RETROVIR

Last updated: February 3, 2026

Executive Summary

RETROVIR (zidovudine) is an antiretroviral drug historically used in the treatment of HIV/AIDS. Initially developed in the late 1980s, it gained rapid market acceptance but has experienced declining sales with the advent of newer, more effective antiretrovirals. This analysis provides a comprehensive review of the current market landscape, regulatory environment, competitive positioning, and future financial projections for RETROVIR as an investment proposition.

---

Overview of RETROVIR

Attribute	Details
Generic Name	Zidovudine (AZT)
Therapeutic Class	Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Original Approval Date	1987 (FDA)
Current Indication	HIV/AIDS, Post-Exposure Prophylaxis (PEP), and potentially for prevention in high-risk groups
Patent Status	Patents expired; marketed as a generic by multiple manufacturers
Production & Supply	Multiple generic manufacturers globally, with some remaining limited patent protections in select markets

---

Market Dynamics

Historical Market Trends

Period	Market Size (USD million)	Growth Rate	Key Factors
2000–2010	$1,200 – $1,800	4% – 6% annually	Entry of newer antiretrovirals, increased treatment options, patent expiries
2011–2022	$1,100 – $1,300	Flat to slight decline	Shift to combination therapies, reduced reliance on monotherapy with RETROVIR

Current Market Landscape (2023)

• Main Markets: United States, EU, China, India
• Market Share: Declining, now under 10% of total HIV treatment prescriptions globally
• Key Competitors: Tenofovir-based regimens, integrase inhibitors (e.g., dolutegravir), fixed-dose combinations

Regulatory & Reimbursement Environment

Regulations & Policies	Impact
WHO Treatment Guidelines (2016)	Reclassified zidovudine as second-line therapy; favoring integrase and NNRTI combinations
U.S. FDA & EMA Policy	Removed from initial treatment recommendations; remains on guidelines for certain populations
Reimbursement Coverage	Mostly limited; often replaced by newer drugs in insurance formularies

Market Challenges

• Declining Demand: Due to superior efficacy, fewer side effects, and simplified dosing of newer drugs
• Price Pressure: Generics driving prices down; margins slim
• Patent Expiries: Although patents are expired or expiring, limited intellectual property protections restrict premium pricing

---

Financial Trajectory

Revenue Outlook (2023–2028)

Year	Estimated Global Revenue (USD million)	Growth/Decline	Assumptions
2023	$50 – $70	Flat to -10%	Continued generic competition, reduced prescribing in developed markets
2024	$40 – $60	-15%	Further market penetration of newer agents, especially in Western markets
2025	$30 – $45	-20%	Transition to niche uses, HIV prevention in specific populations
2026	$20 – $35	-20% to -25%	Market contraction, potential resurgence in certain regions with limited options
2027	$15 – $25	-25%	Diminished role except in resource-limited settings
2028	<$10	Continued decline	Remaining sales driven solely by low-cost markets (e.g., Africa, Asia)

Cost Structure & Profitability

• Manufacturing Costs: Low (~$0.10–$0.20 per unit); margins eroded by pricing pressures
• R&D & Regulatory Investment: Minimal for generic producers; strategic focus on market access
• Profit Margins: Expected to decline further; potential for negative margins in high-cost markets due to price controls

Investment Consideration

Investment Type	Rationale
Long-term commodity asset	Limited upside due to market saturation and declining demand
Niche or combination therapy development	Slight potential if repositioned for specific indications or formulations
Portfolio diversification	Low-return, high-volume, low-margin commodity; not attractive for growth-focused investors

---

Comparison with Alternative Therapies

Therapy Type	Advantages	Disadvantages	Market Positioning Strategy
Tenofovir-based Regimens	Better tolerability, once-daily dosing	Resistance issues in some cases	Mainstream first-line therapy
Integrase Inhibitors (e.g., Dolutegravir)	Superior efficacy, fewer side effects, simplified regimens	Higher upfront cost	Dominates current market
Fixed-Dose Combination Pills	Improved adherence, simplified treatment	Patent restrictions in some cases	Preferred over monotherapy in developed markets

---

Regulatory and Patent Insights

Key Patent Events	Date	Impact
Original Patent Expiration	~2008	Market entry of generics, price reduction
Secondary Patents/Market Exclusivities	Up to 2010	Limited extension in select jurisdictions
Current Patent Status	Expired	No significant patent protections; generic market established

Sources: FDA ANDA database, WHO treatment guidelines, market reports (IQVIA, 2022), and industry publications.

---

Future Outlook and Strategic Recommendations

Growth Opportunities

• Emerging Markets: Continued demand in resource-limited regions where generics remain primary solutions
• Combination Formulations: Potential for low-cost fixed-dose combinations, particularly in developing countries
• Niche Indications: Use in prevention strategies or for resistance management in select populations

Risks and Mitigation

Risk	Mitigation Strategy
Market decline due to newer drugs	Diversify portfolio to include innovative treatments
Price erosion in generics	Optimize manufacturing efficiency
Regulatory shifts favoring newer agents	Invest in R&D for next-generation compounds

---

Key Takeaways

• Market Position: RETROVIR’s market share has significantly declined due to the advent of newer, more effective antiretrovirals.
• Revenue Trajectory: The drug's global sales are projected to decrease steadily over the next five years, with revenues potentially falling below USD 10 million by 2028.
• Investment Potential: Limited for growth-focused investors; more suitable for low-cost, high-volume markets or as part of diversified pharma portfolios.
• Competitive Dynamics: Dominated by advanced therapies with better safety profiles and simplified regimens; generic competition constrains profitability.
• Regulatory Environment: Policies increasingly favor newer, branded drugs; older generics face price pressures and reimbursement hurdles.

---

FAQs

1. Is RETROVIR still a viable therapeutic option for HIV treatment?
While historically significant, RETROVIR is now considered a second-line or niche option, primarily reserved for specific cases or resource-limited settings owing to its side-effect profile and the availability of superior drugs.

2. What are the primary competitors of RETROVIR?
Main competitors include tenofovir-based regimens and integrase inhibitors like dolutegravir, which are favored due to their efficacy, tolerability, and simplified dosing.

3. Are there plans for reformulation or combination therapies involving RETROVIR?
Although some generic manufacturers have explored fixed-dose combinations incorporating zidovudine, the focus has shifted toward newer antiretrovirals, limiting innovation opportunities for RETROVIR itself.

4. How do regulatory trends impact the future of RETROVIR?
Global policies prioritize newer drugs with improved safety and adherence profiles, reducing regulatory support and reimbursement for older drugs like RETROVIR.

5. Which geographic markets still generate notable sales for RETROVIR?
Emerging markets such as India and certain African countries maintain moderate demand due to cost considerations and infrastructure constraints limiting access to newer therapies.

---

References

1. Food and Drug Administration (FDA). Zidovudine (AZT) Approval History. 1987–2022.
2. WHO Consolidated Guidelines on HIV Prevention, Testing, Treatment, and Care. 2016.
3. IQVIA. Global HIV Market Reports. 2022.
4. EMA. Regulatory Status of HIV/AIDS Drugs. 2023.
5. MarketWatch. Pharmaceutical Market Trends and Forecasts. 2022.

---

This report provides a detailed, data-driven analysis suitable for investors, pharmaceutical companies, and healthcare policymakers assessing the future role and investment potential of RETROVIR in HIV therapy.